Adaptive radiation boost study for rectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether giving an extra, targeted radiation dose (adaptive radiation boost) after standard treatment can improve outcomes for people with rectal cancer. You may be eligible if you have stage T2-3 N0-1 rectal cancer and can undergo MRI scans and certain chemotherapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rectal adenocarcinoma (a type of rectal cancer).
- Your cancer is stage T2-3, N0-1, M0 (not spread to distant organs).
- You are willing to have MRI scans and CT scans (or PET-CT) for staging.
- You are at least 18 years old and in good enough health to have daily activities (ECOG 0 or 1).
- Your blood counts and liver function are within normal limits.
- You can take the chemotherapy drugs capecitabine and FOLFOX (or 5-FU or capecitabine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving radiation therapy before surgery for rectal cancer. It uses a higher dose to the tumor during standard radiation to see if it can improve outcomes.
This trial tests a new way of delivering radiation therapy for rectal cancer before surgery. It aims to see if adapting the radiation based on how the tumor shrinks can be more effective and safer than standard treatment.
This study looks at whether two different added “boosts” of radiation can work as well for rectal cancer patients, aiming to avoid or reduce the need for rectal cancer surgery. You would receive a specific combination of radiation (including brachytherapy) and chemotherapy, and your tumor’s location and size will determine if you can take part.
This trial tests a new type of radiation therapy that uses real-time MRI imaging to adjust the radiation precisely to your tumor. It is designed to improve the accuracy of treatment for locally advanced rectal cancer, potentially reducing damage to nearby healthy tissue.
This Phase 1 study tests a radiation treatment approach guided by MRI scans to help keep nearby organs functioning while treating rectal cancer. It is designed to find a safe, effective way to target the tumor and adjust treatment during the course of therapy.
This study tests a “total neoadjuvant” approach—chemotherapy first, then radiation—using adaptive (tailored) radiation planning for people with locally advanced rectal cancer. It may help improve tumor control while adjusting the radiation based on how your cancer and anatomy respond.
Hear when a new Rectum Cancer, Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.